A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination With Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination With Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

The primary purpose of the study is to assess how well amivantamab subcutaneous (SC) administration in combination with lazertinib or in combination with chemotherapy works (antitumor activity) in participants with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC; that is one of the major types of lung cancer).

Start Date16 Dec 2024

Sponsor / Collaborator

Janssen Research & Development LLC

KCT0009698

/ RecruitingNot ApplicableIIT

The first line Lazertinib treatment for metastatic EGFRm NSCLC; the real world evidence in South Korea

Start Date29 Aug 2024

Sponsor / Collaborator

Hallym University Medical Center

KCT0008774

/ RecruitingPhase 2IIT

A randomized, phase 2 trial of lazertinib and chemotherapy combination in EGFR-mutant NSCLC patients without ctDNA clearance after lead-in lazertinib monotherapy (CHAMELEON)

Start Date01 Aug 2024

Sponsor / Collaborator

Yonsei University Severance Hospital

100 Clinical Results associated with Lazertinib

100 Translational Medicine associated with Lazertinib

100 Patents (Medical) associated with Lazertinib

112

Literatures (Medical) associated with Lazertinib

01 Dec 2025·Current Neurology and Neuroscience Reports

Emerging Therapies for Brain Metastases in NSCLC, Breast Cancer, and Melanoma: A Critical Review

Review

Author: Gowda, Maya ; Camacho, Alejandra M ; Ranjan, Tulika ; Ahluwalia, Manmeet S ; Podder, Vivek

PURPOSE OF REVIEW:

Advancements in precision medicine have shifted the treatment paradigm of brain metastases (BM) from non-small cell lung cancer (NSCLC), breast cancer, and melanoma, especially through targeted therapies focused on specific molecular drivers. These novel agents have improved outcomes by overcoming challenges posed by the blood-brain barrier (BBB) and resistance mechanisms, enabling more effective treatment of BM.

RECENT FINDINGS:

In NSCLC, therapies such as osimertinib have improved efficacy in treating EGFR-mutant BM, with emerging combinations such as amivantamab and lazertinib offering promising alternatives for patients resistant to frontline therapies. In HER2-positive breast cancer, significant advancements with tucatinib and trastuzumab deruxtecan (T-DXd) have transformed the treatment landscape, achieving improved survival and intracranial control in patients with BM. Similarly, in triple-negative breast cancer (TNBC), novel therapies such as sacituzumab govitecan (SG) and datopotamab deruxtecan (Dato-DXd) offer new hope for managing BM. For melanoma, the combination of immune checkpoint inhibitors such as nivolumab and ipilimumab has proven effective in enhancing survival for patients with BM, both in BRAF-mutant and wild-type cases. Developing targeted therapies penetrating the BBB has revolutionized BM treatment by targeting key drivers like EGFR, ALK, HER2, and BRAF. Despite improved survival, challenges persist, particularly for patients with resistant genetic alterations. Future research should optimise combination therapies, overcome resistance, and refine treatment sequencing. Continued emphasis on personalized, biomarker-driven approaches offers the potential to further improve outcomes, even for complex cases.

01 Jun 2025·BIOORGANIC & MEDICINAL CHEMISTRY

A clinical review on third and fourth generation EGFR tyrosine kinase inhibitors for the treatment of non-small cell lung cancer

Review

Author: Patel, Harun M ; Patil, Chandragouda R ; Gawli, Chandrakant S

"Epidermal growth factor receptor (EGFR)" mutations are pivotal in the pathogenesis of "Non-Small Cell Lung Cancer (NSCLC)," which is associated with high morbidity and mortality rates. The advent of third and fourth-generation EGFR tyrosine kinase inhibitors (TKIs) has significantly advanced the therapeutic landscape for EGFR-mutant NSCLC, particularly in overcoming resistance mutations such as T790M and C797S. This review delves into the current clinical status, efficacy, safety profiles, and regulatory approvals of third-generation EGFR TKIs, including Osimertinib, Lazertinib, Furmonertinib, Aumolertinib, Rezivertinib, Befotertinib, Sunvozertinib. Furthermore, it explores emerging fourth-generation EGFR TKIs designed to address resistance mechanisms beyond those targeted by their predecessors. Notable fourth-generation candidates such as TQB3804, BPI-361175, BDTX-1535, WJ13404, QLH11811, H002, HS-10375, BBT-207, JIN-A02, and HS-10504 are highlighted for their potential to overcome the C797S mutation. The review emphasizes the importance of these advanced inhibitors in enhancing "progression-free survival and overall survival rates". By evaluating the therapeutic potential and limitations of these EGFR TKIs, this review aims to guide future research in the management of EGFR-mutant NSCLC. This acts as guiding beacon for the strategic design and development of third and fourth generation EGFR-TK inhibitors to overcome the drug resistance hurdles in the development of EGFR-TK inhibitors.

01 May 2025·LUNG CANCER

A cost-effectiveness analysis of amivantamab plus lazertinib versus osimertinib in the treatment of US and Chinese patients with EGFR-mutated advanced non-small cell lung cancer

Article

Author: Li, Qiu ; Qin, Yi ; Wu, Qiuji

BACKGROUND:

The combination of amivantamab and lazertinib (AL) has demonstrated clinically significant efficacy in patients with previously untreated EGFR-mutated advanced non-small cell lung cancer (NSCLC). However, its economic value relative to the standard therapy, osimertinib, remains unclear. This study evaluates the cost-effectiveness of AL regimen compared with osimertinib in US and Chinese healthcare settings.

METHODS:

A partitioned survival model, comprising progression-free survival (PFS), post-progression, and death states, was developed using a Markov model. Clinical data were obtained from the recent Phase III MARIPOSA trial. Direct medical costs (including drug acquisition, administration, and adverse event management) were obtained from US and Chinese healthcare system data, public databases, and the literature. Health-state utilities were sourced from the literature. Incremental cost-effectiveness ratios (ICERs) were calculated based on quality-adjusted life years (QALYs). Threshold analysis was performed to identify pricing strategies at specified willingness-to-pay (WTP) thresholds. Model robustness was assessed through sensitivity and scenario analyses, and additional subgroup analyses performed.

RESULTS:

In the base case analysis, the average costs of AL and osimertinib regimen were $1,030,524.3 (China: $234,270.87) and $466,922.0 (China: $20,075.35), respectively, and the QALYs achieved were 4.08 (China: 3.66) and 2.60 (China: 2.66), respectively. The ICERs for AL compared with osimertinib in the US and China were $563,602.3 and $214,195.51, respectively. Based on the respective WTP thresholds in the US and China, the AL regimen did not represent a cost-effective option. Sensitivity, scenario, and subgroup analyses confirmed the robustness of these findings.

CONCLUSIONS:

Although AL regimen prolongs QALYs compared with osimertinib, it may not meet cost-effectiveness thresholds given current US pricing and simulated Chinese prices. These findings emphasize the need to consider policy implications and future pricing strategies.

161

News (Medical) associated with Lazertinib

15 Apr 2025

·www.biopharmadive.com

J&J keeps forecasts steady as pharma confronts tariff threat

Johnson & Johnson is confident it can manage the impact of tariffs on its pharmaceuticals and medical device businesses this year, announcing Tuesday that it will maintain its financial forecast for the year while raising its sales guidance.J&J, which is the first large drugmaker to report results for the first quarter, expects adjusted earnings per share of $10.60 for 2025. That number is the same as the company estimated in January, before President Donald Trump announced sweeping new tariff policies that will tax imports of medical devices along with most other goods.Duties on drugs are likely coming soon, too. The Trump administration disclosed Monday an investigation into the national security effects of pharmaceutical imports in a move that analysts anticipate will result in new levies in the near future.We built into our guidance about $400 million in tariff costs based on what we know today, said J&J CFO Joe Wolk in a CNBC interview Tuesday morning. It was really a pretty healthy beat considering we didnt have those things in January that were now absorbing.Much of that $400 million impact involves J&Js medical device business, Wolk clarified on a company conference call held later on Tuesday morning, and also reflects retaliatory tariffs China has imposed on U.S. goods.Wolk declined to share an annualized estimate for the impact of tariffs, citing the fast-changing nature of the Trump administrations policies.Yet, for an industry shaken by both Trumps tariff threat and a chaotic regulatory restructuring, J&Js stability may be welcome news.[J&J management] downplayed tariff risks this morning, which we view as an important positive development for perception about the threat to [J&J] and the branded biopharma industry at large, wrote Leerink Partners analyst David Risinger in a client note.Recently, J&J said it will spend $55 billion over the next four years on building new drug factories in the U.S., one of several drugmaker announcements of plans to reshore manufacturing to the U.S. something Trump has leaned specifically on the industry to do. After those plants are complete, J&J expects that essentially all of its advanced medicines will be made in the U.S.Speaking on the companys conference call, J&J CEO Joaquin Duato made the case that tax policy, not tariffs, is more effective at spurring capital investment.Tariffs can create disruptions in the supply chain, leading to shortages, Duato said. If what you want is to build manufacturing capacity in the U.S. ... the most effective answer is not tariffs, but tax policy.The pharmaceutical industry benefited mightily from the tax law passed in 2017 during Trumps first administration, and is arguing for its renewal.Its unclear what kind of pharma tariffs might emerge from the newly begun probe by the Department of Commerce. According to a regulatory notice posted Monday, Commerce will look at both branded and generic medicines, as well as the active drug ingredients they contain and the starting materials from which theyre derived.Trump has threatened duties between 50% and 200%, which, if imposed, would dramatically increase costs for an industry that has supply chains spread throughout Europe and Asia. Most precursor chemicals and active ingredients are sourced from China and India, while many branded manufacturers have production facilities in countries like Ireland, Switzerland, the Netherlands and Singapore.Wolk, in his CNBC interview, speculated that the administration might focus on generic medicines and precursor chemicals, but stressed that was only J&Js view of where national security concerns might be most acute.I think its also important that companies in healthcare partner with the administration to look to mitigate some of the vulnerabilities that exist today in other healthcare supply chains, said Duato, on the conference call. It is important for us to partner with the administration ... and we plan to do it.Overall, J&J reported sales of about $21.9 billion during the first three months of the year, an increase of 2.4% from the same period the year prior and higher than consensus Wall Street estimates. Revenue from the companys pharma business also beat expectations, totaling roughly $13.9 billion in the quarter.J&J executives highlighted on the call several of the companys approved medicines and two experimental therapies for which it thinks analysts forecasts are too low. Notably, the company expects sales of its cancer drug combination Rybrevant and Lazcluze to reach about twice as high in 2027 as Wall Streets current estimate of $1.8 billion.Shares were trading down about 0.5% by mid-morning Tuesday. '

15 Apr 2025

·www.investor.jnj.com

Johnson & Johnson Reports Q1 2025 Results

2025 First-Quarter reported sales growth of 2.4% to $21.9 Billion with operational growth of 4.2%* and adjusted operational growth of 3.3%* 2025 First-Quarter earnings per share (EPS) increased to $4.54 which includes the reversal of special charges and adjusted EPS increased to $2.77 or 2.2%* Significant new product pipeline progress including approval of TREMFYA in Crohn’s disease, data for RYBREVANT/LAZCLUZE overall survival in non-small cell lung cancer and icotrokinra in plaque psoriasis, and initiation of the clinical trial for a general surgery robotic system, OTTAVA Company increases Full-Year 2025 operational sales2,5 guidance to reflect the addition of CAPLYTA following the completion of the Intra-Cellular Therapies acquisition Including tariff costs, dilution from the Intra-Cellular Therapies acquisition, and updated foreign exchange, Company maintains Full-Year 2025 adjusted reported EPS4 outlook of 6.2%* growth at the mid-point NEW BRUNSWICK, N.J.--(BUSINESS WIRE)-- Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2025. “The power of Johnson & Johnson’s uniquely diversified portfolio was on full display this quarter, with strong operational sales growth reinforcing our confidence in 2025 guidance,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “During the quarter, we fortified our position as an innovation powerhouse with major advancements across our pipeline, including TREMFYA in IBD, RYBREVANT plus LAZCLUZE in non-small-cell lung cancer, and OTTAVA, our soft tissue surgical robotic system, and further enhanced our leading neuroscience portfolio with the completion of the Intra-Cellular Therapies acquisition.” Overall financial results Q1 ($ in Millions, expect EPS) 2025 2024 % Change Reported Sales $21,893 $ 21,383 2.4% Net Earnings $10,999 $3,255 237.9% EPS (diluted) $4.54 $1.34 238.8% Q1 Non-GAAP* ($ in Millions, except EPS) 2025 2024 % Change Operational Sales1,2 4.2% Adjusted Operational Sales1,3 3.3% Adjusted Net Earnings1,4 $6,706 $6,580 1.9% Adjusted EPS (diluted)1,4 $2.77 $2.71 2.2% Free Cash Flow6,7 ~$3,400 $2,850 1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules 2 Excludes the impact of translational currency 3 Excludes the net impact of acquisitions and divestitures and translational currency 4 Excludes intangible amortization expense and special items 5 Excludes COVID-19 Vaccine 6 Non-GAAP measure; defined as cash flow from operating activities, less additions to property, plant and equipment. Cash flow from operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings. 7 First-quarter 2025 is estimated as of April 15, 2025 Regional sales results Q1 % Change ($ in Millions) 2025 2024 Reported Operational1,2 Currency Adjusted Operational1,3 U.S. $12,305 $11,620 5.9% 5.9 - 4.4 International 9,588 9,763 (1.8) 2.1 (3.9) 1.9 Worldwide $21,893 $21,383 2.4% 4.2 (1.8) 3.3 1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules 2 Excludes the impact of translational currency 3 Excludes the net impact of acquisitions and divestitures and translational currency Segment sales results Q1 % Change ($ in Millions) 2025 2024 Reported Operational1,2 Currency Adjusted Operational1,3 Innovative Medicine $13,873 $13,562 2.3% 4.2 (1.9) 4.4 MedTech 8,020 7,821 2.5 4.1 (1.6) 1.3 Worldwide $21,893 $21,383 2.4% 4.2 (1.8) 3.3 1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules 2 Excludes the impact of translational currency 3 Excludes the net impact of acquisitions and divestitures and translational currency First-Quarter 2025 segment commentary: Operational sales* reflected below excludes the impact of translational currency. Innovative Medicine Innovative Medicine worldwide operational sales grew 4.2%* driven primarily by DARZALEX, CARVYKTI, ERLEADA, and RYBREVANT/LAZCLUZE in Oncology, TREMFYA and SIMPONI/SIMPONI ARIA in Immunology, SPRAVATO in Neuroscience, and XARELTO in Cardiovascular/Metabolism/Other. Growth was partially offset by an approximate (810) basis points impact from STELARA in Immunology. MedTech MedTech worldwide operational sales grew 4.1%*, with net acquisitions and divestitures positively impacting growth by 2.8%. Growth was driven primarily by Abiomed in Cardiovascular and wound closure products in General Surgery. Growth was partially offset by Spine, Sports & Other in Orthopaedics. Full-year 2025 guidance: Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses, and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP. ($ in Billions, except EPS) April 2025 January 2025 Adjusted Operational Sales1,2,5 Change vs. Prior Year / Mid-point 2.0% – 3.0% / 2.5% 2.0% – 3.0% / 2.5% Operational Sales2,5 / Mid-point Change vs. Prior Year / Mid-point $91.6B – $92.4B / $92.0B 3.3% – 4.3% / 3.8% $90.9B – $91.7B / $91.3B 2.5% – 3.5% / 3.0% Estimated Reported Sales3,5/ Mid-point Change vs. Prior Year / Mid-point $91.0B – $91.8B / $91.4B 2.6% – 3.6% / 3.1% $89.2B – $90.0B / $89.6B 0.5% – 1.5% / 1.0% Adjusted Operational EPS (Diluted)2,4 / Mid-point Change vs. Prior Year / Mid-point $10.50 – $10.70 / $10.60 5.2% – 7.2% / 6.2% $10.75 – $10.95 / $10.85 7.7% – 9.7% / 8.7% Adjusted EPS (Diluted)3,4 / Mid-point Change vs. Prior Year / Mid-point $10.50 – $10.70 / $10.60 5.2% – 7.2% / 6.2% $10.50 – $10.70 / $10.60 5.2% – 7.2% / 6.2% 1 Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures 2 Non-GAAP financial measure; excludes the impact of translational currency 3 Calculated using Euro Average Rate: April 2025 = $1.10 and January 2025 = $1.04 (Illustrative purposes only) 4 Non-GAAP financial measure; excludes intangible amortization expense and special items 5 Excludes COVID-19 Vaccine Other modeling considerations will be provided on the webcast. Notable announcements in the quarter: The information contained in this section should be read together with Johnson & Johnson’s other disclosures filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. The reader is also encouraged to review all other news releases and information available in the Investor Relations section of the company’s website at News Releases, as well as Innovative Medicine News Center, MedTech News & Events, and www.factsabouttalc.com. Regulatory European Commission approves subcutaneous RYBREVANT (amivantamab) for the treatment of patients with advanced EGFR-mutated non-small cell lung cancer1 Press Release European Commission approves Johnson & Johnson’s subcutaneous DARZALEX (daratumumab)-based quadruplet regimen for the treatment of patients with newly diagnosed multiple myeloma, regardless of transplant eligibility1 Press Release U.S. FDA approves TREMFYA (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn's disease Press Release Nipocalimab, the first and only investigational treatment to be granted U.S. FDA Breakthrough Therapy designation for the treatment of adults with moderate-to-severe Sjögren's disease, has now received Fast Track designation Press Release Data Releases Johnson & Johnson MedTech Announces Completion of First Cases with OTTAVA Robotic Surgical System1 Press Release Icotrokinra results show 75% of adolescents with plaque psoriasis achieved completely clear skin and demonstrate favorable safety profile in a once daily pill1 Press Release Johnson & Johnson highlights new data that showcase the strength of nipocalimab, demonstrating long-term sustained disease control in adults living with generalized myasthenia gravis (gMG)1 Press Release TREMFYA (guselkumab) is the first and only IL-23 inhibitor to significantly reduce both the signs and symptoms and the progression of structural damage in adults living with active psoriatic arthritis1 Press Release Johnson & Johnson MedTech to Highlight Latest Advancements in Heart Disease Treatment with Impella at ACC.25 Press Release RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) outperforms osimertinib with a significant and unprecedented overall survival benefit in patients with EGFR-mutated non-small cell lung cancer Press Release New nipocalimab data and real-world research at AAN 2025 highlight positive Phase 3 results and commitment to people living with generalized myasthenia gravis (gMG) Press Release RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) significantly outperforms standard of care in first-line EGFR-mutated lung cancer with compelling new data at ELCC 2025 Press Release Johnson & Johnson MedTech Showcases New Era of Digital Orthopaedics at AAOS 2025 Press Release Icotrokinra meets primary endpoint of clinical response in ulcerative colitis study and shows potential to transform the treatment paradigm for patients Press Release Icotrokinra results show potential to set a new standard of treatment in plaque psoriasis Press Release TREMFYA (guselkumab) subcutaneous (SC) induction data support potential to be the first and only in its class to offer the option of both intravenous and SC induction therapy in ulcerative colitis Press Release New nipocalimab data published in mAbs journal details differentiated molecular design, clinical profile and potential of nipocalimab to treat IgG-driven alloantibody and autoantibody diseases Press Release Findings from pivotal nipocalimab Phase 3 study in a broad antibody positive population of people living with generalized myasthenia gravis (gMG) published in The Lancet Neurology Press Release Product Launch Shockwave Medical Launches Novel Forward Intravascular Lithotripsy Platform in U.S. to Transform Treatment of Difficult-to-Cross Calcified Lesions Press Release Other Johnson & Johnson Closes Landmark Intra-Cellular Therapies, Inc. Acquisition to Solidify Neuroscience Leadership1 Press Release Johnson & Johnson to Return to Tort System to Defeat Meritless Talc Claims1 Press Release Johnson & Johnson Increases U.S. Investment to More than $55 Billion Over the Next Four Years Press Release Johnson & Johnson Announces Darren Snellgrove as Vice President, Investor Relations Press Release Webcast information: Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website. A replay and podcast will be available approximately two hours after the live webcast in the Investor Relations section of the company's website at events-and-presentations. About Johnson & Johnson: At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at www.jnj.com. Non-GAAP financial measures: * “Operational sales growth” excluding the impact of translational currency, “adjusted operational sales growth” excluding the net impact of acquisitions and divestitures and translational currency, as well as “adjusted net earnings”, “adjusted diluted earnings per share” and “adjusted operational diluted earnings per share” excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the company's website at quarterly results. Copies of the financial schedules accompanying this earnings release are available on the company’s website at quarterly results. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including adjusted income before tax by segment, an Innovative Medicine pipeline of selected compounds in late stage development and a copy of today’s earnings call presentation can also be found in the Investor Relations section of the company's website at quarterly results. Note to investors concerning forward-looking statements: This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, and market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations or changes to applicable laws and regulations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans, including restructuring plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; and increased scrutiny of the health care industry by government agencies. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. Percent Change 2025 2024 Total Operations Currency $ 8,092 7,612 6.3 % 6.3 - 5,781 5,950 (2.9 ) 1.5 (4.4 ) 13,873 13,562 2.3 4.2 (1.9 ) 4,213 4,008 5.1 5.1 - 3,807 3,813 (0.2 ) 3.0 (3.2 ) 8,020 7,821 2.5 4.1 (1.6 ) 12,305 11,620 5.9 5.9 - 9,588 9,763 (1.8 ) 2.1 (3.9 ) $ 21,893 21,383 2.4 % 4.2 (1.8 ) Percent Change 2025 2024 Total Operations Currency $ 12,305 11,620 5.9 % 5.9 - 5,110 5,163 (1.0 ) 2.2 (3.2 ) 1,167 1,194 (2.3 ) 9.2 (11.5 ) 3,311 3,406 (2.8 ) (0.6 ) (2.2 ) 9,588 9,763 (1.8 ) 2.1 (3.9 ) $ 21,893 21,383 2.4 % 4.2 (1.8 ) 2025 2024 Percent Percent Percent Increase Amount to Sales Amount to Sales (Decrease) $ 21,893 100.0 $ 21,383 100.0 2.4 7,357 33.6 6,511 30.4 13.0 14,536 66.4 14,872 69.6 (2.3 ) 5,112 23.3 5,257 24.6 (2.8 ) 3,225 14.7 3,542 16.6 (8.9 ) (128 ) (0.6 ) (209 ) (1.0 ) (7,321 ) (33.4 ) 2,404 11.2 17 0.1 164 0.8 13,631 62.3 3,714 17.4 267.0 2,632 12.1 459 2.2 473.4 $ 10,999 50.2 $ 3,255 15.2 237.9 $ 4.54 $ 1.34 238.8 2,423.8 2,430.1 19.3 % 12.4 % $ 8,011 36.6 $ 7,877 36.8 1.7 $ 6,706 30.6 $ 6,580 30.8 1.9 $ 2.77 $ 2.71 2.2 16.3 % 16.5 % 2025 2024 $10,999 $3,255 (6,966) 2,726 1,120 1,078 55 171 132 148 39 (20) - 51 - 9 1,315 (856) 12 18 $6,706 $6,580 2,423.8 2,430.1 $2.77 $2.71 $2.81 1 2 2.3% 2.5% 2.4% 6.3% 5.1% 5.9% (2.9)% (0.2)% (1.8)% (1.9) (1.6) (1.8) - - - (4.4) (3.2) (3.9) 4.2% 4.1% 4.2% 6.3% 5.1% 5.9% 1.5% 3.0% 2.1% (3.3) (1.2) (5.1) (1.8) (1.4) (0.5) 0.2 0.5 0.3 0.0 0.9 0.3 0.4 0.2 0.3 4.4% 1.3% 3.3% 6.3% 0.9% 4.4% 1.9% 1.8% 1.9% REPORTED SALES vs. PRIOR PERIOD ($MM) 2025 2024 Reported Operational (1) Currency $ 3,013 2,383 26.4 % 26.4 % - 2,664 2,430 9.6 % 14.4 % -4.8 % 5,678 4,814 17.9 % 20.4 % -2.5 % 318 140 * * - 51 16 * * * 369 157 * * * 1,829 1,464 24.9 % 24.9 % - 1,409 1,228 14.7 % 19.8 % -5.1 % 3,237 2,692 20.3 % 22.5 % -2.2 % 292 285 2.5 % 2.5 % - 479 404 18.5 % 23.1 % -4.6 % 771 689 11.9 % 14.6 % -2.7 % 235 265 -11.5 % -11.5 % - 474 518 -8.5 % -4.2 % -4.3 % 709 784 -9.5 % -6.7 % -2.8 % 113 36 * * - 28 11 * * * 141 47 * * * 68 50 35.2 % 35.2 % - 18 8 * * * 86 58 48.4 % 50.2 % -1.8 % 105 101 4.9 % 4.9 % - 46 33 38.8 % 45.9 % -7.1 % 151 133 13.3 % 15.0 % -1.7 % 7 9 -24.3 % -24.3 % - 118 172 -31.3 % -28.5 % -2.8 % 125 181 -30.9 % -28.3 % -2.6 % 47 33 42.9 % 42.9 % - 42 41 4.6 % 10.1 % -5.5 % 89 73 21.7 % 24.7 % -3.0 % REPORTED SALES vs. PRIOR PERIOD ($MM) 2025 2024 Reported Operational (1) Currency 2,196 2,453 -10.5 % -10.5 % - 1,510 1,794 -15.8 % -11.5 % -4.3 % 3,707 4,247 -12.7 % -10.9 % -1.8 % 314 266 18.1 % 18.1 % - 10 27 -64.2 % -64.2 % - 143 141 1.3 % 6.8 % -5.5 % 467 434 7.5 % 9.3 % -1.8 % 292 254 14.8 % 14.8 % - 366 299 22.4 % 29.7 % -7.3 % 659 554 18.9 % 22.9 % -4.0 % 981 1,396 -29.8 % -29.8 % - 644 1,055 -38.9 % -35.8 % -3.1 % 1,625 2,451 -33.7 % -32.3 % -1.4 % 599 509 17.6 % 17.6 % - 356 299 19.2 % 24.4 % -5.2 % 956 808 18.2 % 20.1 % -1.9 % 1 0 * * - 0 0 - - - 1 0 * * - 968 1,054 -8.1 % -8.1 % - 679 749 -9.3 % -5.5 % -3.8 % 1,647 1,803 -8.6 % -7.0 % -1.6 % 38 41 -7.4 % -7.4 % - 110 136 -18.9 % -15.2 % -3.7 % 148 177 -16.3 % -13.4 % -2.9 % 625 765 -18.2 % -18.2 % - 277 292 -4.9 % -1.1 % -3.8 % 903 1,056 -14.5 % -13.5 % -1.0 % 276 191 45.0 % 45.0 % - 43 34 25.0 % 31.7 % -6.7 % 320 225 41.9 % 42.9 % -1.0 % 28 58 -50.6 % -50.6 % - 248 287 -13.4 % -9.8 % -3.6 % 277 345 -19.6 % -16.7 % -2.9 % REPORTED SALES vs. PRIOR PERIOD ($MM) 2025 2024 Reported Operational (1) Currency 744 766 -2.9 % -2.9 % - 281 283 -0.6 % 3.2 % -3.8 % 1,025 1,049 -2.3 % -1.2 % -1.1 % 363 356 2.1 % 2.1 % - 159 169 -6.0 % -2.5 % -3.5 % 522 524 -0.5 % 0.6 % -1.1 % 365 392 -6.9 % -6.9 % - 86 76 13.4 % 17.5 % -4.1 % 451 468 -3.6 % -2.9 % -0.7 % 15 18 -12.7 % -12.7 % - 37 39 -4.6 % -0.3 % -4.3 % 52 56 -7.2 % -4.3 % -2.9 % 315 324 -2.8 % -2.8 % - 487 497 -1.9 % 1.9 % -3.8 % 802 821 -2.2 % 0.1 % -2.3 % 8 8 -1.3 % -1.3 % - 350 315 11.0 % 14.7 % -3.7 % 358 323 10.7 % 14.3 % -3.6 % 305 314 -2.9 % -2.9 % - 98 104 -6.2 % -0.6 % -5.6 % 403 418 -3.7 % -2.3 % -1.4 % 2 2 7.7 % 7.7 % - 39 77 -48.8 % -47.0 % -1.8 % 41 78 -47.6 % -45.9 % -1.7 % 855 631 35.4 % 35.4 % - 158 197 -19.7 % -15.3 % -4.4 % 1,013 829 22.3 % 23.4 % -1.1 % 690 518 33.3 % 33.3 % - - - - - - 690 518 33.3 % 33.3 % - 165 114 45.0 % 45.0 % - 158 197 -19.7 % -15.3 % -4.4 % 323 311 3.9 % 6.7 % -2.8 % 8,092 7,612 6.3 % 6.3 % - 5,781 5,950 -2.9 % 1.5 % -4.4 % $ 13,873 13,562 2.3 % 4.2 % -1.9 % REPORTED SALES vs. PRIOR PERIOD ($MM) FIRST QUARTER % Change 2025 2024 Reported Operational (1) Currency $ 1,261 1,025 23.0 % 23.0 % - 842 781 7.8 % 10.7 % -2.9 % 2,103 1,806 16.4 % 17.7 % -1.3 % 684 692 -1.1 % -1.1 % - 638 652 -2.0 % 0.7 % -2.7 % 1,323 1,344 -1.6 % -0.2 % -1.4 % 339 303 11.9 % 11.9 % - 81 67 19.7 % 23.6 % -3.9 % 420 371 13.3 % 14.0 % -0.7 % 206 - * * - 52 - * * - 258 - * * - 32 30 7.1 % 7.1 % - 72 62 15.1 % 17.4 % -2.3 % 103 92 12.5 % 14.1 % -1.6 % 1,384 1,448 -4.4 % -4.4 % - 857 892 -3.9 % -0.9 % -3.0 % 2,241 2,340 -4.2 % -3.1 % -1.1 % 263 270 -2.5 % -2.5 % - 146 152 -4.0 % -0.8 % -3.2 % 409 422 -3.1 % -1.9 % -1.2 % 231 242 -4.3 % -4.3 % - 158 160 -1.0 % 2.1 % -3.1 % 389 401 -3.0 % -1.7 % -1.3 % 502 504 -0.5 % -0.5 % - 270 261 3.7 % 7.2 % -3.5 % 772 765 0.9 % 2.1 % -1.2 % 388 432 -10.2 % -10.2 % - 283 320 -11.6 % -8.9 % -2.7 % 671 752 -10.8 % -9.7 % -1.1 % REPORTED SALES vs. PRIOR PERIOD ($MM) FIRST QUARTER % Change 2025 2024 Reported Operational (1) Currency 1,002 987 1.5 % 1.5 % - 1,394 1,429 -2.5 % 0.8 % -3.3 % 2,396 2,416 -0.8 % 1.1 % -1.9 % 457 446 2.7 % 2.7 % - 616 641 -4.0 % -1.0 % -3.0 % 1,073 1,087 -1.2 % 0.5 % -1.7 % 544 542 0.5 % 0.5 % - 778 788 -1.2 % 2.3 % -3.5 % 1,323 1,330 -0.5 % 1.6 % -2.1 % 566 547 3.4 % 3.4 % - 713 710 0.4 % 3.9 % -3.5 % 1,279 1,258 1.7 % 3.7 % -2.0 % 452 438 3.1 % 3.1 % - 467 472 -1.1 % 2.4 % -3.5 % 919 910 1.0 % 2.7 % -1.7 % 114 110 4.3 % 4.3 % - 246 238 3.4 % 7.1 % -3.7 % 361 348 3.7 % 6.2 % -2.5 % 4,213 4,008 5.1 % 5.1 % - 3,807 3,813 -0.2 % 3.0 % -3.2 % $ 8,020 7,821 2.5 % 4.1 % -1.6 % 2023 2024 2024 Full Year Q1 Q2 Q3 Q4 Full Year 66 36 52 68 101 257 27 11 17 21 21 70 93 47 69 89 122 327 56 50 59 64 68 241 7 8 9 12 17 46 63 58 69 75 85 287 93 33 37 36 39 145 235 41 45 50 36 172 328 73 83 86 75 317 1,292 356 376 417 408 1,557 681 169 171 166 162 668 1,973 524 548 583 570 2,225 79 18 17 21 19 75 182 39 49 39 38 165 260 56 67 60 57 240 19 2 5 3 1 11 1,395 77 227 54 43 401 1,414 78 233 56 45 412 First Quarter March 30, 2025 GAAP Intangible asset amortization Litigation related Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Tax legislation and other tax related First Quarter March 30, 2025 Non-GAAP $ 4,020 (649 ) 3,371 2,261 2,261 2,548 2,548 (166 ) - - - (20 ) (18 ) - (204 ) 5,210 649 - - 20 18 - 5,897 First Quarter March 30, 2025 GAAP Intangible asset amortization Litigation related Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Tax legislation and other tax related First Quarter March 30, 2025 Non-GAAP $ 3,326 (471 ) (8 ) (52 ) 2,795 2,656 2,656 677 (6 ) 671 (60 ) - - (47 ) (54 ) (21 ) - (182 ) 1,421 471 - 55 112 21 - 2,080 First Quarter March 30, 2025 GAAP Intangible asset amortization Litigation related Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Tax legislation and other tax related First Quarter March 30, 2025 Non-GAAP $ 11 11 195 195 - (7,206 ) - 6,966 - - - - (240 ) 7,000 - (6,966 ) - - - - 34 First Quarter March 30, 2025 GAAP Intangible asset amortization Litigation related Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Tax legislation and other tax related First Quarter March 30, 2025 Non-GAAP $ 7,357 (1,120 ) (8 ) (52 ) - 6,177 5,112 5,112 3,225 (6 ) 3,219 (7,321 ) - 6,966 (30 ) (74 ) (39 ) (498 ) - - (128 ) (128 ) 17 (17 ) - 13,631 1,120 (6,966 ) 55 132 39 - 8,011 2,632 188 (1,553 ) 11 30 9 (12 ) 1,305 10,999 932 (5,413 ) 44 102 30 12 6,706 $ 3,370 (698 ) (2 ) 2,670 2,438 2,438 2,896 (7 ) 2,889 (111 ) (144 ) (47 ) 55 (247 ) 4,969 698 - 144 47 (55 ) - 9 - 5,812 $ 3,120 (380 ) (7 ) (20 ) 2,713 2,582 (4 ) 2,578 646 (18 ) (27 ) 601 (47 ) (20 ) (43 ) (22 ) (132 ) 1,520 380 - 27 61 22 51 - - 2,061 $ 21 21 237 237 - - 2,517 (2,726 ) (40 ) (13 ) (262 ) (2,775 ) - 2,726 - 40 13 - - - 4 $ 6,511 (1,078 ) (7 ) (20 ) (2 ) 5,404 5,257 (4 ) 5,253 3,542 (18 ) (27 ) (7 ) 3,490 2,404 (2,726 ) (130 ) 20 (432 ) - - (209 ) (209 ) 164 (164 ) - 3,714 1,078 2,726 171 148 (20 ) 51 9 - 7,877 459 148 627 39 38 (7 ) 9 2 (18 ) 1,297 3,255 930 2,099 132 110 (13 ) 42 7 18 6,580 Media contact: media-relations@its.jnj.com Investor contact: investor-relations@its.jnj.com

Clinical ResultPhase 3Breakthrough TherapyDrug ApprovalFinancial Statement

15 Apr 2025

·www.biospace.com

J&J Beats Q1 Analyst Estimates Thanks To Tremfya, Carvykti, While Stelara Fades

iStock, BrasilNut1 J&J opened Q1 2025 pharma earnings Tuesday, reporting sales of $21.9 billion and diluted earnings per share of $4.54. The medicines unit provided $13.9 billion while the medtech unit generated the remaining $8 billion. Johnson & Johnson’s medicines, including Tremfya and Carvykti, helped drive a worldwide sales increase of 2.4% in the first quarter, the company reported Tuesday morning. As always, J&J was the first out the gate for pharma earnings, reporting sales of $21.9 billion and diluted earnings per share of $4.54. The medicines unit provided $13.9 billion while the medtech unit kicked in the remaining $8 billion. Guggenheim called the first quarter results “solid” in a Tuesday morning note, as the company beat the firm’s sales estimate of $21.63 billion. J&J also maintained its guidance for 2025, despite facing major challenges from tariff threats that have sent the broader market on a rollercoaster ride. The company expects adjusted operation sales of 2-3%. Guggenheim noted that J&J is now factoring the tariffs into its guidance for 2025, although details were not provided. Leerink Partners called the guidance maintenence “a welcome relief,” as J&J’s medtech unit is particularly vulnerable to potential tariffs. CEO Joaquin Duato name-dropped Tremfya and Rybrevant as the key medicines behind J&J’s success this quarter in a Tuesday morning statement . Tremfya, which is approved for Crohn’s disease, had worldwide sales of $956 million, an 18% increase over $808 million for the same quarter in 2024. J&J’s fading immunology star Stelara, meanwhile, suffered a setback in the quarter as biosimilars crept into the market. Another headwind was changes to the Medicare’s Part D policies. The drug pulled in sales of $1.63 billion for the first quarter, compared to $2.45 billion for the same period in 2023, representing a 34% decline. Duato also highlighted clinical milestones for Rybrevant and its small cell lung cancer combo med Lazcluze. The combo outperformed AstraZeneca’s lung cancer stalwart Tagrisso in a Phase III head-to-head trial that read out in March. J&J’s combo led to a significant increase in overall survival as compared to Tagrisso. The combo brought in $141 million, compared to $47 million for the period a year ago. J&J will address investors in a first quarter earnings call at 8:30 a.m. ET. Guggenheim expects investors will have more questions about macro headwinds like tariffs than J&J’s usual operations. “We do not believe the 1Q 2025 results fundamentally change the overall JNJ story, with investors likely focusing more on current macro factors (e.g., tariffs, taxes, healthcare utilization, etc...), and their impact on JNJ and its peers, and potentially less focus than usual on JNJ’s current growth drivers and pipeline assets,” the firm wrote.

Phase 3Drug ApprovalFinancial StatementClinical ResultBiosimilar

100 Deals associated with Lazertinib

External Link

KEGG	Wiki	ATC	Drug Bank
D11980	-	-	DB16216

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
EGFR-mutated non-small Cell Lung Cancer	Japan	Janssen Pharmaceutical KK	27 Mar 2025
EGFR exon 21 Substitution Mutant Non-small Cell Lung Cancer	United States	Janssen Biotech, Inc.	19 Aug 2024
EGFR exon 19 Deletions Mutant Non-small Cell Lung Cancer	South Korea	Yuhan Corp.	18 Jan 2021
EGFR T790M Mutation Positive Non-Small Cell Lung Carcinoma	South Korea	Yuhan Corp.	18 Jan 2021

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Lung Non-Small Cell Carcinoma	Phase 3	United States	Janssen Research & Development LLC	05 Aug 2022
Advanced Lung Non-Small Cell Carcinoma	Phase 3	China	Janssen Research & Development LLC	05 Aug 2022
Advanced Lung Non-Small Cell Carcinoma	Phase 3	Japan	Janssen Research & Development LLC	05 Aug 2022
Advanced Lung Non-Small Cell Carcinoma	Phase 3	Argentina	Janssen Research & Development LLC	05 Aug 2022
Advanced Lung Non-Small Cell Carcinoma	Phase 3	Australia	Janssen Research & Development LLC	05 Aug 2022
Advanced Lung Non-Small Cell Carcinoma	Phase 3	Brazil	Janssen Research & Development LLC	05 Aug 2022
Advanced Lung Non-Small Cell Carcinoma	Phase 3	Canada	Janssen Research & Development LLC	05 Aug 2022
Advanced Lung Non-Small Cell Carcinoma	Phase 3	France	Janssen Research & Development LLC	05 Aug 2022
Advanced Lung Non-Small Cell Carcinoma	Phase 3	Germany	Janssen Research & Development LLC	05 Aug 2022
Advanced Lung Non-Small Cell Carcinoma	Phase 3	Israel	Janssen Research & Development LLC	05 Aug 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04487080 (MARIPOSA, ESMO_ELCC2025) Manual	Phase 3	EGFR-mutated non-small Cell Lung Cancer First line EGFR L858R \| EGFR Exon 19 Deletion	-	Amivantamab plus Lazertinib	acepcwnkas(dflhlwocrw) = qxiduggtpf fyidceqwjv (nmsqfkdrig, 42.9 - NE) View more	Positive	26 Mar 2025
				Osimertinib	acepcwnkas(dflhlwocrw) = vhschqhqnx fyidceqwjv (nmsqfkdrig, 33.4 - 41.0) View more
NCT04077463 (CHRYSALIS-2, ESMO_ELCC2025) Manual	Phase 1	EGFR-mutated non-small Cell Lung Cancer EGFR Mutation	49	Amivantamab plus Lazertinib	muuccavvmc(rwrdhufzde) = jkmvsscvir bghtgbkpte (gueektnxny ) View more	Positive	26 Mar 2025
				EGFR TKIs (Osimertinib, Afatinib)	muuccavvmc(rwrdhufzde) = iuuidulyqe bghtgbkpte (gueektnxny ) View more
NCT05469022 (ESMO_ELCC2025)	Phase 2	Lung Cancer Neoadjuvant \| Adjuvant EGFR mutations	128	Neoadjuvant lazertinib therapy	lkfluurxbn(flwrvphdqo) = knngrhjwnc zfvaiiclhw (kkfygtyjbc ) View more	Positive	26 Mar 2025
NCT04487080 (MARIPOSA, Company_Website) Manual	Phase 3	Non-Small Cell Lung Cancer First line EGFR Exon 19 Deletion \| EGFR L858R	1,074	RYBREVANT+LAZCLUZE	rvipitugxk(ghaanfshlt) = clinically meaningful and statistically significant improvement in OS versus the current standard of care osimertinib. Improvement in median OS is expected to exceed one year. zopzvmhpwi (jjywaembkp ) Met	Positive	07 Jan 2025
				osimertinib
NCT04077463 (CHRYSALIS-2, Pubmed) Manual	Phase 1	EGFR-mutated non-small Cell Lung Cancer EGFR L858R \| EGFR Exon 19 Deletion	162	Amivantamab 1050 mg + Lazertinib 240 mg	oopjassovy(cgiegopkiz) = pbdwvlqzjb jrpgiaqxln (kjlonkqbjb, 22 - 36) View more	Positive	02 Jan 2025
NCT05786430 (LUCAS, ESMO_ASIA2024) Manual	Phase 2	EGFR-mutated non-small Cell Lung Cancer EGFR Mutation	54	Lazertinib + Pemetrexed + Carboplatin	xzxvxqureo(nprfmvtdid) = egufvzlrml zrnubgedfr (wycfqlqzgt, 5.16 - 9.56) View more	Positive	07 Dec 2024
NCT04487080 (MARIPOSA, CTgov)	Phase 3	EGFR-mutated non-small Cell Lung Cancer \| Locally Advanced Lung Non-Small Cell Carcinoma	1,074	Amivantamab+Lazertinib (Experimental: Arm A (Open-label): Amivantamab + Lazertinib)	jlkvzohgff(uzlwqwytlb) = kmfpuraqrv jaabafqgbg (sdmomucwfs, kskhhlpnpq - avnyquqrex) View more	-	09 Oct 2024
				Lazertinib+Osimertinib (Active Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching Lazertinib)	jlkvzohgff(uzlwqwytlb) = qomqhnoyuz jaabafqgbg (sdmomucwfs, sjogpxuyrq - axxtxkhuli) View more
NCT03046992 (LASER201, Pubmed \| BMC Med) Manual	Phase 1/2	EGFR T790M Mutation Positive Non-Small Cell Lung Carcinoma Second line \| Last line \| Third line EGFR T790M	78	Lazertinib 240 mg/day	kaaiftiagf(qyuatitvtx) = cmpeebmfho thzxhunzdt (oskhrcsqfj ) View more	Positive	08 Oct 2024
NCT04487080 (MARIPOSA, FDA_CDER) Manual	Phase 3	Non-Small Cell Lung Cancer First line EGFR Exon 19 Deletion \| EGFR L858R	858	RYBREVANT in combination with lazertinib	qahydgbmuk(nptvutvhdp) = abxemzfmmb ptlsfxsmug (mpmatzalfr, 19.1 - 27.7) View more	Positive	19 Sep 2024
				Osimertinib	qahydgbmuk(nptvutvhdp) = xcglqewdzs ptlsfxsmug (mpmatzalfr, 14.8 - 18.5) View more
NCT05277701 (ESMO2024) Manual	Phase 2	Non-Small Cell Lung Cancer First line uncommon EGFR mutation	36	Lazertinib 240mg	vyitlcshjd(oecajjdhok) = vadkdljios wuebxbmzaz (mzzoulinxu ) View more	Positive	14 Sep 2024
				Lazertinib 240mg (G719X)	vyitlcshjd(oecajjdhok) = niplrbjunx wuebxbmzaz (mzzoulinxu )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis